Table 2.
Treatment and response
|
Patient number
|
1st chemo therapy
|
2nd chemo therapy
|
MAHA baseline
|
MAHA day 14
|
PFS in wk
|
RS in wk
|
OS in wk
|
||||
|
|
|
|
Pts
|
Hb
|
Sch
|
Plt
|
Hb
|
Sch
|
|
|
|
| 1 | FLO | FOLFIRI | 8 | 5.9 | 31 | 84 | 9.6 | 12 | 9 | 1.1 | 10.3 |
| 2 | No | NA | 32 | 7.7 | 40 | NA | NA | NA | 0.1 | NA | 0.1 |
| 3 | FLO | Paclitaxel | 34 | 8.0 | 15 | 65 | 10.7 | - | 25.7 | 0.1 | 27.1 |
| 4 | FOLFIRI-Ram1 | NA | 168 | 5.4 | 40 | 204 | 11.6 | - | 32.1 | NA | NA |
| 5 | FLOT | No | 130 | 7.8 | 35 | NA | NA | NA | 1.0 | NA | 1.0 |
| 6 | FLOT | FOLFIRI-Ram | 44 | 8.4 | 25 | 208 | 8.8 | 25 | 25.4 | 2.3 | 28.0 |
| 7 | FLOT | No | 46 | 6.9 | 97 | NA | NA | NA | 0.3 | NA | 0.3 |
| 8 | No | NA | 36 | 8.2 | 17 | NA | NA | NA | 1.86 | NA | 1.86 |
1
Diagnosis of microsatellite instability-high tumor. FLO: 5-Fluorouracil (5-FU), leucovorin, oxaliplatin; FLOT: 5-FU, leucovorin, oxaliplatin, docetaxel; FOLFIRI: 5-FU, leucovorin, irinotecan; Hb: Hemoglobin (gram per deciliter); NA: Not applicable; OS: Overall survival; PFS: Progression-free survival; Plt: Platelet count (per nanoliter); RAM: Ramucirumab; RS: Residual survival; Sch: Schistocytes (per milliliter).